07 · 08 · 19 - Our clients - ABG-IP
Nucaps Nanotechnology, South Summit 2019 finalist
23 · 05 · 19 - Our clients - ABG-IP
Tractivus, Seal of Excellence of the European Commission
26 · 03 · 19 - Our clients - ABG-IP
Omomyc, the Myc inhibitor developed by Peptomyc, is closer to the clinic
19 · 09 · 18 - Our clients - ABG IP
Spherium Biomed announces clinical trial Cyclatop is safe and efficacious for Atopic Dermatitis
28 · 06 · 18 - Our clients - ABG IP
Peptomyc S.L. wins the Best Business Initiative Award at the 25th Young Entrepreneur Awards
22 · 05 · 18 - Our clients - ABG IP
Spherium Biomed announces positive outcome of a phase I/IIa clinical trial for Mucomel®
24 · 04 · 18 - Our clients - ABG IP
Spherium Biomed completed enrolment in the Cyclatop© (SP14019) trial in February 2018
19 · 04 · 18 - Our clients - ABG IP
Spherium Biomed has signed a licensing agreement with Simini Technologies from Canada
15 · 03 · 18 - Our clients - ABG IP
Atlas Molecular Pharma, approval for the treatment of Congenital Erythropoietic Porphyria